Log in
Enquire now
DiogenX

DiogenX

DiogenX is a regenerative diabetes treatment founded in 2019 by Jean-Pascal Tranié, Benjamin Charles and Patrick Collombat.

OverviewStructured DataIssuesContributors

Contents

diogenx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Pharmaceutical industry
Pharmaceutical industry
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Diabetes mellitus
Diabetes mellitus
Regenerative medicine
Regenerative medicine
...
Location
France
France
Marseille
Marseille
0
Nice
Nice
0
B2X
B2C
B2C
CEO
‌
Benjamin Charles
0
Founder
‌
Patrick Collombat
0
‌
Benjamin Charles
0
‌
Jean-Pascal Tranié
0
Pitchbook URL
pitchbook.com/profiles...436149-19
Number of Employees (Ranges)
1 – 10
Full Address
180 avenue du Prado 13008 Marseille0
Parc Valrose – Centre de Biochimie 06108 Nice cedex 2 France0
Investors
Advent France Biotechnology
Advent France Biotechnology
0
Founded Date
January 1, 2019
Total Funding Amount (USD)
35,100,000
Latest Funding Round Date
May 10, 2023
Latest Funding Type
Series A
Series A
Country
France
France
0
Headquarters
Marseille
Marseille

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
30,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like DiogenX

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.